| Literature DB >> 15939339 |
Csilla Ozvegy-Laczka1, Judit Cserepes, N Barry Elkind, Balázs Sarkadi.
Abstract
Recent antitumor drug research has seen the development of a large variety of tyrosine kinase inhibitors (TKIs) with increasing specificity and selectivity. These are highly promising agents for specific inhibition of malignant cell growth and metastasis. However, their therapeutic potential also depends on access to their intracellular targets, which may be significantly affected by certain ABC membrane transporters. It has been recently shown that several human multidrug transporter ABC proteins interact with specific TKIs, and the ABCG2 transporter has an especially high affinity for some of these kinase inhibitors. These results indicate that multidrug resistance protein modulation by TKIs may be an important factor in the treatment of cancer patients; moreover, the extrusion of TKIs by multidrug transporters may result in tumor cell TKI resistance. Interaction with multidrug resistance ABC transporters may also significantly modify the pharmacokinetics and toxicity of TKIs in patients.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15939339 DOI： 10.1016/j.drup.2005.02.002
Source DB: PubMed Journal: Drug Resist Updat ISSN： 1368-7646 Impact factor: 18.500